APA (7th ed.) Citation

Motzer, R. J., McDermott, D. F., Escudier, B., Burotto, M., Choueiri, T. K., Hammers, H. J., . . . Tannir, N. M. (2022). Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer, 128(11), 2085-2097. https://doi.org/10.1002/cncr.34180

Chicago Style (17th ed.) Citation

Motzer, Robert J., et al. "Conditional Survival and Long‐term Efficacy with Nivolumab Plus Ipilimumab Versus Sunitinib in Patients with Advanced Renal Cell Carcinoma." Cancer 128, no. 11 (2022): 2085-2097. https://doi.org/10.1002/cncr.34180.

MLA (9th ed.) Citation

Motzer, Robert J., et al. "Conditional Survival and Long‐term Efficacy with Nivolumab Plus Ipilimumab Versus Sunitinib in Patients with Advanced Renal Cell Carcinoma." Cancer, vol. 128, no. 11, 2022, pp. 2085-2097, https://doi.org/10.1002/cncr.34180.